Literature DB >> 11532188

ABO-incompatibility in solid organ transplantation.

L Rydberg1.   

Abstract

The most important transplantation antigen system in solid organ transplantation is the ABO histo-blood group system. Crossing the ABO barrier in solid organ transplantation is usually not done except for emergency liver transplantations. Early experiences of crossing the ABO barrier in renal transplantation were very disappointing. In the 1970s, clinical trials were started transplanting kidneys of subgroup A2 into blood group O recipients. The tissues of the A2 subgroup expresses reduced amount of A antigens compared to subgroup A1 and the recipients had no special pretreatment and standard immunosuppression. A number of early graft losses were experienced but the trial also resulted in several long time surviving grafts. A few centres have adapted the concept of A2 to non A kidney transplantations with successful results, when the recipient anti-A titres are low or reduced prior to transplantation. In the early 1980s one group successfully transplanted A1 and B kidneys from living related donors across the ABO-barrier using an immunosuppressive protocol consisting of quadruple drugs and splenectomy and this protocol was adapted by a few other groups. In Japan, where cadaver donors are available in very limited number, the largest number of ABO-incompatible transplantations have been performed. Altogether more than 300 ABO-incompatible kidney transplantations have been performed in more than 40 centres since 1989. ABO-incompatible liver transplantations have been performed mainly in emergency cases and the results have generally been inferior to ABO-compatible grafts. In children below the age of three years, liver transplantations across the ABO-barrier have been quite successful especially with living related donors. Very few ABO-incompatible heart/heart-lung/lung-transplantations have been reported with a few successful cases, but the majority have been failures. Recently a series of ABO-incompatible heart transplants performed in small children have been reported with a high success rate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532188     DOI: 10.1046/j.1365-3148.2001.00313.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  29 in total

1.  [ABO blood group expression in corneal allograft failures].

Authors:  N Ardjomand; P Komericki; A Klein; D Mattes; Y El-Shabrawi; H Radner
Journal:  Ophthalmologe       Date:  2005-10       Impact factor: 1.059

2.  Vienna experience of ABO-incompatible living-donor kidney transplantation.

Authors:  Michael Haidinger; Sabine Schmaldienst; Günther Körmöczi; Heinz Regele; Afschin Soleiman; Dieter Schwartz; Kurt Derfler; Rudolf Steininger; Ferdinand Mühlbacher; Georg A Böhmig
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Blood Group A antigen expression on cardiac endothelium is highly individualized: possible implications for transplantation.

Authors:  Eric A Gehrie; Justin M Cates; Hui Nian; Sandy J Olson; Pampee P Young
Journal:  Cardiovasc Pathol       Date:  2013-01-04       Impact factor: 2.185

4.  Lessons learnt from living donor liver transplantation with ABO-incompatibility: A single-centre experience from southern India.

Authors:  Surumi Shajahan; Sreedurga Thottanchery Sasidharan; Sudhindran Surendran; Veena Shenoy; Uma Devi Padma
Journal:  Indian J Gastroenterol       Date:  2019-03-08

Review 5.  The role of plasmapheresis in critical illness.

Authors:  Trung C Nguyen; Joseph E Kiss; Jordana R Goldman; Joseph A Carcillo
Journal:  Crit Care Clin       Date:  2012-07       Impact factor: 3.598

Review 6.  Accommodation in ABO-incompatible organ transplants.

Authors:  Mayara Garcia de Mattos Barbosa; Marilia Cascalho; Jeffrey L Platt
Journal:  Xenotransplantation       Date:  2018-05       Impact factor: 3.907

Review 7.  Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange.

Authors:  Daniel S Warren; Robert A Montgomery
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 8.  Therapeutically targeting protein-glycan interactions.

Authors:  A Rek; E Krenn; A J Kungl
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 9.  Liver transplantation: yesterday, today and tomorrow.

Authors:  Osman Abbasoglu
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

Review 10.  ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Nina Worel
Journal:  Transfus Med Hemother       Date:  2015-10-29       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.